Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Care Bare Rx vs Maves

Care Bare Rx
Graded #43

Higher grade

vs+3.200000000000003
Maves
Graded #89

Lower grade

The verdict

Care Bare Rx takes it — 75/100 to 71.8/100.

Care Bare Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Oral as well as injectable routes for both molecules plus a brand Ozempic lane, bundled with hair, TRT and sexual health.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +16
68
84
Dose & formulationCare Bare Rx +29
94
65
Clinical oversightMaves +2
74
76
Labs & monitoringCare Bare Rx +10
62
52
FulfillmentMaves +9
78
87
Contract termsCare Bare Rx +17
72
55
Care Bare Rx · left barMaves · right bar

The numbers

MetricCare Bare RxMaves
WeighScore75/10071.8/100
GradeCC
Scorecard rank#43#89
SemaglutideFrom $199/mo (shared weight-loss price)$99/mo (starting dose, first-month rate, compounded)
TirzepatideFrom $199/mo (shared weight-loss price)Not disclosed
CoverageMulti-stateAll 50 states
Brand-name accessYesYes
Oral / sublingualYesInjection only
Care Bare Rx

Graded #43 · C

Strengths

  • Oral tirzepatide as well as injectable — rare on this board
  • Brand Ozempic (from $705/mo) and oral Rybelsus beside the compounded line
  • LegitScript certified and HIPAA compliant
  • One platform if you also want hair, TRT, sexual health or NAD+

Where it loses points

  • The advertised "from $199/mo" is one figure shared across all weight-loss treatments — neither molecule priced separately
  • Per-dose pricing is quiz-gated, so a titrated cost cannot be modelled beforehand
  • No named clinicians, founding year or parent company disclosed
  • Compounded medication is not FDA-approved the way brand Ozempic, Wegovy, or Zepbound are
Maves

Graded #89 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard